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ANTIMICROBIAL RESISTANCE HAS EMERGED as animportant issue influencing patient mortal-
ity and overall resource utilization in the inten-
sive care unit (ICU) setting [1–3]. Intensive care
units worldwide are faced with increasingly
rapid emergence and spread of antibiotic-resis-
tant bacteria. Both gram-negative and gram-pos-
itive bacteria resistant to antibiotics are reported
as important causes of hospital-acquired infec-
tions [4–12]. In many circumstances, particularly
with methicillin-resistant Staphylococcus aureus
(MRSA), Enterococcus faecium, and gram-nega-
tive bacteria producing extended-spectrum
beta-lactamase (ESBL) enzymes with resistance
to multiple other antibiotics, few agents remain
for effective treatment [13–20].
Intensive care units are an important area for
the emergence of antimicrobial resistance be-
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ABSTRACT
Objective: To assemble the available clinical data on the prevention of antimicrobial resis-
tance in the intensive care unit (ICU) setting.
Data Source: A MEDLINE database search and references from identified articles were em-
ployed to obtain the literature relating to the prevention of antimicrobial resistance in the ICU.
Conclusions: The ICU presents a unique environment for the conduct of clinical research.
The closed physical space with centralized patient management and efficient data recovery
allows important clinical questions to be evaluated in a timely manner. Antimicrobial resis-
tance has emerged as an important determinant of mortality for patients in the ICU. Addi-
tionally, there is currently a limited pipeline of new agents for the treatment of emerging bac-
teria with new resistance genes that pose an increasing threat to the ICU patient. Effective
strategies for the prevention of antimicrobial resistance within ICUs are available and should
be implemented aggressively. These strategies can be divided into non-pharmacologic infec-
tion-control strategies (e.g., routine hand hygiene, infection-specific prevention protocols) and
antibiotic management strategies (e.g., shorter courses of appropriate antibiotics, narrowing
of the antimicrobial spectrum on the basis of culture results). Additional studies conducted
in ICUs are needed urgently to identify the optimal approaches for the management of an-
tibiotics in order to balance the need for efficacy with the ability to minimize resistance.
Pulmonary and Critical Care Division, Washington University School of Medicine, Barnes Jewish Hospital, St. Louis,
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cause of the frequent use of broad-spectrum an-
tibiotics, the crowding of patients with high
levels of disease acuity within relatively small
specialized areas, reductions in nursing and
other support staff because of economic pres-
sures (increasing the likelihood of person-to-
person transmission of microorganisms), and
the presence of more chronically and acutely ill
patients who require prolonged hospitalization
and often harbor antibiotic-resistant bacteria
[2,21,22]. Therefore, it makes sense to employ
the ICU as a model for the conduct of clinical
research aimed at curbing or at least minimiz-
ing this problem. Many of the strategies de-
scribed below have been developed in the ICU
setting but also are applicable in other areas of
the hospital. In general, these interventions
simply attempt to balance the somewhat-com-
peting goals of providing appropriate antimi-
crobial treatment to critically ill patients while
avoiding the unnecessary administration of an-
tibiotics. It is this balance that needs to drive
future clinical research in the area of resistance.
The strategies described in this review adhere
to the Centers for Disease Control and Preven-
tion 12-step program for the prevention of an-
timicrobial resistance (http://www.cdc.gov/
drugresistance/healthcare). One of the key el-
ements in this strategy is to consult experts in
the field of antimicrobial resistance (e.g., infec-
tious disease experts, infection control practi-
tioners, microbiologists) when designing inter-
ventions aimed at minimizing the emergence
of antimicrobial resistance.
ANTIBIOTIC EXPOSURE IS THE MAIN
RISK FACTOR FOR ANTIMICROBIAL
RESISTANCE
A number of investigators have demonstrated
a close association between the use of antibiotics
and the emergence of subsequent antibiotic re-
sistance in both gram-negative and gram-posi-
tive bacteria [23–33]. Therefore, strategies aimed
at limiting or modifying the administration of
antimicrobial agents have the greatest likelihood
of preventing resistance to these agents. Other
factors promoting antimicrobial resistance in-
clude prolonged hospitalization; the presence of
invasive devices such as endotracheal tubes and
intravascular catheters, possibly because of the
formation of biofilms on their surfaces; resi-
dence in long-term treatment facilities; and in-
adequate infection control practices [22]. The
emergence of new strains of existing pathogens
within the community has created additional
stressors favoring the entry of resistant mi-
croorganisms into the ICU. This has been
demonstrated most recently by the identifica-
tion and spread of community-associated me-
thicillin-resistant S. aureus (CA-MRSA) [34,35].
However, prolonged regimens of antimicrobial
agents appear to be the most important factor
promoting the emergence of antibiotic resis-
tance, one that is potentially amenable to inter-
vention [36,37].
ANTIBIOTIC RESISTANCE AS A
DETERMINANT OF HOSPITAL
MORTALITY AND HIGHER 
HEALTH CARE COSTS
Antimicrobial regimens lacking activity
against identified microorganisms causing se-
rious infections (i.e., inappropriate antimicro-
bial therapy) are associated with greater hos-
pital mortality [38–47]. More recently, the same
finding has been demonstrated for patients
with severe sepsis [48–51]. Unfortunately,
changing antimicrobial therapy to an appro-
priate regimen after susceptibility data become
available does not improve clinical outcomes
[40,44,46]. These studies suggest that escalating
resistance has led to greater overall hospital
mortality, in part through the administration of
less effective antimicrobial agents. The recent
Infectious Diseases Society of America/Amer-
ican Thoracic Society (IDSA/ATS) guidelines
for the treatment of ventilator-associated pneu-
monia (VAP) emphasize the importance of in-
appropriate antimicrobial therapy as a de-
terminant of hospital mortality [52]. These
guidelines also stress the importance of main-
taining local, frequently updated antibiograms
within individual hospitals and ICUs to ensure
the appropriateness of antibiotic coverage and
the use of proper drug doses to optimize the
tissue concentrations of antibiotics.
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In addition to increased hospital mortality, an-
timicrobial resistance is associated with excess
costs. Most of this cost is associated with the ac-
quisition of nosocomial infections, many of which
are potentially caused by antibiotic-resistant bac-
teria [33,53]. However, resistance may actually
confer added morbidity and costs as well. For ex-
ample, MRSA infections are associated with
worse clinical outcomes than those attributable to
methicillin-sensitive S. aureus (MSSA). Cosgrove
et al., in a meta-analysis of 30 investigations fo-
cusing on bacteremia, concluded that MRSA bac-
teremia independently increased the risk of death
[54]. Similarly, Blot et al. observed that the mor-
tality difference attributable to MRSA relative to
MSSA was approximately 25% [55].
All of these efforts have been limited by lack
of information about two key confounders:
Severity of illness and administration of inap-
propriate antibiotic therapy. Generally, sub-
jects who develop infections with MRSA are
more severely ill, both at admission and at the
time of diagnosis, than subjects infected with
MSSA. Patients with VAP caused by MRSA
also tend to have been hospitalized longer than
similar persons with MSSA infection. Most
careful investigators have attempted to control
for confounding by severity. We recently con-
ducted a retrospective analysis of a large co-
hort of subjects with bronchoscopically con-
firmed VAP caused by S. aureus, which
suggested that MRSA infection has important
effects on ICU length of stay and healthcare
costs [56]. That is, independent of major con-
tributors to ICU length of stay, such as sever-
ity of illness, duration of mechanical ventila-
tion, and administration of appropriate
antibiotic therapy, MRSA increased the ICU
hospitalization by nearly 50%. Correcting for
outliers and for those who consume substan-
tial resources by restricting the analysis to ICU-
free days confirmed the disproportionate im-
pact of MRSA on ICU bed use. Assuming
conservatively that the cost per day of ICU care
equals $2,000 in the U.S., one can compute that
each case of MRSA VAP amplified hospital
costs by at least $10,000 to $15,000. Therefore,
there is an economic motive, along with a clin-
ical efficacy motive, for attempting to minimize
the emergence of antibiotic resistance.
WHAT STRATEGIES PREVENT
ANTIMICROBIAL RESISTANCE?
Infection control strategies
In general, strategies aimed at the prevention
of nosocomial infections caused by antibiotic-
resistant bacteria should be employed routinely
in all ICUs (Table 1). These interventions can be
separated into two broad categories: Specific in-
terventions aimed at the primary prevention of
nosocomial infections (e.g., catheter-associated
bacteremia, VAP) and the use of infection con-
trol practices to prevent horizontal transmission
of antibiotic-resistant bacteria.
Hand hygiene and protective barriers
Hand hygiene is still the most important
and effective measure to prevent horizontal
transmission of antibiotic-resistant nosoco-
mial pathogens [57,58]. Unfortunately, greater
patient workloads and decreased staffing
have contributed to poor compliance with
handwashing and other routine infection con-
trol measures, especially in the ICU [59]. Al-
ternative hand hygiene methods using alcohol
solutions have been developed that are effec-
tive, do not require sinks, can be performed
more rapidly than traditional handwashing
using soap solutions in order to improve com-
pliance, and are more effective at reducing
bacterial colony counts on the hands (60,61).
The use of gowns and gloves also reduces hor-
izontal transmission of antibiotic-resistant
bacterial pathogens [62,63]. Therefore, appro-
priate hand disinfection and barrier precau-
tions should be employed to reduce transmis-
sion of antibiotic-resistant bacteria in the ICU
[64]. The importance of employing routine
barrier precautions has been amplified with
the emergence of antibiotic-resistant strains of
Clostridium difficile that possess added viru-
lence attributable both to antibiotic resistance
and to the elaboration of a binary toxin
[64–66].
The use of hand hygiene, universal gloving,
and strict contact precautions appears to be
most important in patients colonized or at high
risk for colonization with antibiotic-resistant
bacteria [67]. Additionally, the use of surveil-
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lance cultures to identify patients colonized
with antibiotic-resistant bacteria, allowing
them to be placed in isolation in an efficient
manner, may help to reduce the spread of re-
sistant bacteria [63,68]. Nevertheless, contro-
versy exists over the optimal use of strict iso-
lation precautions typically employing sterile
gloves, gowns, and more aggressive surveil-
lance practices to prevent the spread of resis-
tant microbes [69,70]. One potential concern
about these techniques is that they may pose a
safety issue if health care workers have less
contact with critically ill patients [71]. How-
ever, the threat and consequences of horizon-
tal cross-infection with antibiotic-resistant bac-
teria probably outweigh the potential risks of
isolation practices in the ICU setting.
Surveillance to detect antimicrobial resistance
Antimicrobial surveillance appears to be a
reasonable strategy for detecting the presence
of antibiotic-resistant organisms. This may al-
low the application of both appropriate con-
tact precautions and the prescription of ap-
propriate antimicrobial treatment. Michel et al.
recently evaluated twice-weekly quantitative
surveillance cultures of endotracheal aspirates
in all intubated patients who were receiving
mechanical ventilation to assist in the choice
TABLE 1. STRATEGIES TO PREVENT RESISTANCE IN THE ICU
P: Prophylactic administration of antibiotics should be discouraged unless clinically indicated in high-risk
patients.
R: Routine appropriate (i.e., active against the identified pathogen) and adequate (e.g., optimal dosing, duration
of therapy) treatment of infections.
E: Encourage avoidance of unnecessary use of antimicrobial agents (e.g., empiric antibiotics in the absence of
clinical and microbiologic data supporting the presence of infection).
V: Ventilator-associated pneumonia and other specific infection prevention and treatment protocols should be
establisned for the local ICU.
E: Employ antiseptic techniques for all invasive procedures.
N: Noncompliance with local infection prevention and antibiotic treatment protocols should not be tolerated.
T: Try always to de-escalate to more narrow-spectrum antibiotic regimens on the basis of culture results and
antimicrobial susceptibility data.
R: Restricted formulary control for specific antimicrobial agents or drug classes if there are outbreaks of
antibiotic-resistant bacteria.
E: Evade antimicrobial homogeneity. Promote appropriate use of multiple drug classes (e.g., avoid highly
restricted antibiotic formularies; consider use of antimicrobial mixing).
S: Strict isolation precautions for patients at high risk for (e.g., patients transferred from long-term care facilities)
or found to have infection/colonization with clinically important antibiotic-resistant bacteria.
I: Infectious disease consultation for difficult-to-manage antibiotic-resistant infections and infection control
problems.
S: Systematic disinfection of commonly used instruments, devices, patient care materials, and rooms between
uses.
T: Teach infection control procedures and optimal antibiotic utilization practices to all staff participating in the
care of ICU patients.
A: Active culture surveillance programs to identify patients infected/colonized with clinically important
antibiotic-resistant bacteria.
N: Narrow-spectrum antibiotics should be used when appropriate on the basis of microbiology data.
C: Cease appropriate antibiotics for bacterial infections 24 to 48 hours after achieving an appropriate clinical
response.
E: Embrace locally developed antibiotic guidelines and protocols aimed at balancing antimicrobial efficacy and
preventing the emergence of resistance.
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of antibiotic when VAP was suspected [72]. In
34 of 41 cases (83%), pre-VAP endotracheal as-
pirate cultures identified the same pathogens
with similar antibiotic susceptibility patterns
as cultures of bronchoalveolar lavage (BAL)
fluid obtained when VAP was suspected, and
the antibiotic selected on the basis of the re-
sults of endotracheal aspirate cultures was ap-
propriate in 38 patients (95%). In contrast, had
the original ATS Guidelines [73] or those of
Trouillet et al. [33] been followed, the empiric
antibiotic treatment would have been appro-
priate in only 68% and 83% of the patients, re-
spectively. The main reason for the inappro-
priate coverage using the published guidelines
was the failure to treat highly resistant
pathogens. In addition to the better coverage,
antibiotic selection on the basis of pre-VAP en-
dotracheal aspirate cultures reduced the un-
necessary use of some antibiotics, such as the
-lactam agents, compared with strategies
based on the original ATS and Trouillet guide-
lines [33,73]. The results of this study suggest
that twice-weekly quantitative surveillance
cultures of endotracheal aspirates will assist in
the early prescription of appropriate antibiotic
treatments for patients who develop VAP. This
strategy may improve clinical outcomes, re-
duce antibiotic resistance within ICUs, and
lower hospitalization costs.
Infection-specific protocols and guidelines
Several focused clinical efforts have demon-
strated the potential for practice guidelines or
protocols promoting sound clinical practices
to reduce the rates of VAP [74–79]. Similarly,
prevention programs have reduced the occur-
rence of nosocomial bacteremia by achieving
higher rates of compliance with basic preven-
tion practices [80–84]. These protocols and
guidelines apply well-accepted practices for
infection-specific prevention (e.g., use of ster-
ile gowns/masks/gloves and full drapes dur-
ing catheter insertion to prevent catheter-as-
sociated bacteremia; drainage of ventilator
circuit condensate) that are promoted in
mandatory education programs. The success
of such interventions depends on the degree
to which they are accepted by the local ICU
community and overall compliance with their
implementation [85,86].
Reducing ICU length of stay
The duration of ICU stay and of mechanical
ventilation are important risk factors for the de-
velopment of infections caused by antibiotic-
resistant bacteria [33,87]. Therefore, efforts
aimed at reducing the duration of hospitaliza-
tion or exposure to high-risk environments
such as the ICU could also reduce the occur-
rence of infections or colonization attributable
to antibiotic-resistant pathogens. Noninvasive
mechanical ventilation is one accepted ap-
proach to minimizing the duration of hospital-
ization secondary to respiratory failure; its use
has been associated with a lower risk of noso-
comial infection [88–90].
Avoidance of the biofilm burden
Biofilms form on surfaces such as endotra-
cheal tubes or urinary catheters when they are
encountered by bacteria that settle on them and
upregulate genes involved in matrix produc-
tion [91]. The colonies of bacteria forming the
biofilm and detaching from it are under the
control of chemical signals of the same type
that regulate quorum sensing, and these regu-
latory molecules guide the formation of the
slime-enclosed microcolonies and water chan-
nels that make up the biofilm. Certain bacteria,
such as Pseudomonas species, appear to be more
capable of forming biofilms [92]. Biofilms ap-
pear to promote the emergence of antibiotic re-
sistance by limiting the access of antibiotics to
the bacteria and by inducing the production of
chemicals promoting antibiotic resistance [93].
Currently, biofilm prevention technology has
been applied only to urinary catheters and cen-
tral venous catheters.
In general, invasive devices such as central
venous catheters should be removed as soon as
clinically indicated, as they promote the emer-
gence of infections with antibiotic-resistant
bacteria. However, for individuals who cannot
be managed without these devices, antimicro-
bial-coated intravascular and urinary catheters
have been associated with reductions in noso-
comial infection rates [94–96]. Interestingly, a
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recent in vitro study found that subinhibitory
concentrations of aminoglycoside antibiotics
induce biofilm formation by Pseudomonas
aeruginosa and Escherichia coli [97]. In P. aerugi-
nosa, a gene, designated “aminoglycoside re-
sponse regulator” (arr), is essential for this in-
duction and contributes to biofilm-specific
aminoglycoside resistance. Therefore, it ap-
pears that the degree of antibiotic penetration
into a tissue compartment such as the lung 
can determine whether antibiotic resistance
emerges. This finding has been the impetus for
the evaluation of aerosolized aminoglycosides
as an adjunct for the treatment of gram-nega-
tive bacterial pneumonia.
Vaccines
Vaccines for the prevention of antibiotic-re-
sistant bacterial infections are not currently
available for clinical use in the ICU setting.
However, conjugate vaccine-induced antibod-
ies to S. aureus have been demonstrated to re-
duce blood-stream infection with this pathogen
among patients requiring chronic hemodialy-
sis [98]. Investigation of this vaccine among po-
tential ICU patient populations is ongoing [99].
More importantly, the threat of pandemic
avian influenza not only carries the risk of a
large proportion of the population succumbing
to this disease but the threat of greater antibi-
otic resistance secondary to the likely wide-
spread empiric use of antibiotics during the flu
outbreak. This risk has resulted in international
efforts to develop a vaccine against this im-
portant threat [100].
ANTIBIOTIC MANAGEMENT
STRATEGIES
Formal protocols and guidelines
Antibiotic practice guidelines or protocols
have emerged as a potentially effective means
of both avoiding unnecessary antibiotic ad-
ministration and increasing the effectiveness
of prescribed antibiotics (Fig. 1). Automated
antimicrobial utilization guidelines have been
successful in identifying and minimizing the
occurrence of adverse effects secondary to an-
tibiotic administration and to better antibiotic
selection [101,102]. Their use has also been as-
sociated with stable antibiotic susceptibility
patterns for both gram-positive and gram-
negative bacteria, possibly as a result of pro-
FIG. 1. Antimicrobial treatment algorithm aimed at providing appropriate initial treatment to patients while mon-
itoring clinical response along with microbiologic data to facilitate antimicrobial de-escalation (e.g., more narrow-
spectrum regimen, shortest course of therapy according to individual patient clinical response).
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moting antimicrobial heterogeneity and spe-
cific endpoints for antibiotic discontinuation
[103,104]. Automated and nonautomated an-
timicrobial guidelines have also been em-
ployed to reduce the overall use of antibiotics
and to limit the use of inappropriate antimi-
crobial treatment, both of which could impact
the development of antibiotic resistance
[41,105,106]. One way these guidelines limit
the unnecessary use of antimicrobial agents is
by recommending that initial prescriptions for
empiric broad-spectrum antibiotics be modi-
fied when the culture results reveal that nar-
row-spectrum antibiotics can be employed in-
stead [106]. This practice is described as
“antimicrobial de-escalation.” Unfortunately,
clinicians appear to be reluctant to de-escalate
despite the emerging evidence in favor of this
concept [107].
Hospital formulary restrictions
Restricted use of specific antibiotics or an-
tibiotic classes from the hospital formulary has
been employed to reduce the occurrence of an-
tibiotic resistance as well as drug acquisition
costs [22]. Although such an approach can
achieve reductions in pharmacy expenses and
adverse reactions attributable to the restricted
drugs [108], not all experiences have been suc-
cessful; indeed, some have been associated
with higher overall antibiotic costs [109]. Re-
stricted use of specific antibiotics has generally
been applied to those with a broad spectrum of
action (e.g., carbapenems), rapid emergence of
antibiotic resistance (e.g., cephalosporins), and
readily identified toxicity (e.g., aminoglyco-
sides). To date, it has been difficult to demon-
strate that restricted hospital formularies are ef-
fective in curbing the overall emergence of
antibiotic resistance. This may be secondary in
large part to methodologic problems. How-
ever, their use has been successful in specific
outbreaks of infection with antibiotic-resistant
bacteria, particularly in conjunction with infec-
tion control practices and antibiotic educational
activities [30,110,111]. It is important to note
that implementation of this type of interven-
tion will be successful only if such outbreaks
are recognized. This requires a systematic ap-
proach to patient surveillance for the detection
of potentially antibiotic-resistant bacteria and a
microbiology laboratory that can detect the
presence of resistance. The latter is not always
a simple matter, especially for the detection of
gram-negative bacteria possessing ESBL en-
zymes [30,31].
Use of narrow-spectrum antibiotics
Another proposed strategy to curtail the de-
velopment of antimicrobial resistance, in addi-
tion to the judicious overall use of antibiotics, is
to use drugs with a narrow antimicrobial spec-
trum. Several investigations have suggested that
infections such as community-acquired pneu-
monia can usually be treated successfully with
narrow-spectrum agents, especially if the infec-
tions are not life threatening [112, 113]. Similarly,
avoidance of broad-spectrum antibiotics (e.g.,
cephalosporins) and reintroduction of narrow-
spectrum agents (e.g., penicillin, trimethoprim,
gentamicin) along with infection control prac-
tices have reduced the occurrence of C. difficile
infections [114]. Unfortunately, ICU patients of-
ten have already received antimicrobial treat-
ment, making it more likely that they will be in-
fected with an antibiotic-resistant pathogen [33].
Additionally, pathogens in the community have
changed with the advent of more antibiotic-re-
sistant bacteria such as MRSA and the increas-
ing presence of risk factors for health care-
acquired infections [115]. Therefore, initial em-
piric treatment with broad-spectrum agents is
often necessary for ICU patients to avoid inap-
propriate treatment until culture results become
available [42,43].
Quantitative cultures and assessment 
of infection risk
Pneumonia is the most common hospital-ac-
quired infection among mechanically ventilated
patients [3,116]. Unfortunately, establishing a
definite diagnosis is difficult because of the non-
specific signs and symptoms associated with
this infection. This, in turn, has resulted in
largely empiric treatment for VAP. A recent
meta-analysis of four randomized trials demon-
strated that quantitative bacterial cultures of
material obtained from the lower respiratory
tract may facilitate de-escalation of empiric
broad-spectrum antibiotics and reduce drug-
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specific days of treatment [117]. Another recent
study found that patients with a clinical suspi-
cion of VAP and culture-negative BAL results
for a major pathogen could safely have antimi-
crobial therapy discontinued within 72 h [118].
Interestingly, the mean modified clinical pul-
monary infection score of these patients was
approximately six, suggesting that this quanti-
tative clinical assessment of the risk for VAP
could have been employed to discontinue an-
tibiotics [119].
Combination antibiotic therapy
Several recent meta-analyses recommend the
use of monotherapy with a beta-lactam antibi-
otic as opposed to combination therapy includ-
ing an aminoglycoside for the definitive treat-
ment of neutropenic fever and severe sepsis
once antimicrobial susceptibilities are known
[120,121]. Additionally, there is no definitive ev-
idence that the emergence of antibiotic resis-
tance is reduced by combination antimicrobial
therapy. However, empiric combination ther-
apy directed against high-risk pathogens such
as P. aeruginosa should be encouraged until the
results of antimicrobial susceptibility testing be-
come available. Such an approach to empiric
treatment can increase the likelihood of pro-
viding appropriate initial antimicrobial therapy
with improved outcomes [47]. Patients at high
risk for infection with potentially antibiotic-re-
sistant bacteria usually can be identified by the
presence of factors such as prior antibiotic ex-
posure and longer hospitalization preceding the
onset of nosocomial infection [33].
Antibiotic cycling and scheduled antibiotic
changes
The concept of antibiotic class cycling has
been suggested as a strategy for reducing the
emergence of antimicrobial resistance [122]. In
theory, a class of antibiotics or a specific antibi-
otic drug is withdrawn from use for a defined
time and reintroduced later in an attempt to
limit bacterial resistance to the cycled antimi-
crobial agents. This offers the potential for an-
tibiotic classes that possess greater overall ac-
tivity against the predominant ICU pathogens
to be used, resulting in more effective treatment
of nosocomial infections. Unfortunately, math-
ematical modeling suggests that the use of an-
tibiotic cycling will be inferior to mixing of an-
tibiotics as a strategy to reduce the emergence
of resistance [123]. Nevertheless, several earlier
studies of antimicrobial cycling have found
beneficial outcomes in terms of antibiotic resis-
tance, with benefits extending outside the ICU
setting [124–127]. Because of methodological
limitations, including the introduction of un-
controlled changes in infection control and the
lack of appropriate control groups, interpreta-
tion of these studies has been difficult.
Two recent studies attempted to minimize
the influences of confounding effects in order
to evaluate the role of antimicrobial cycling on
resistance. Warren et al., employing scheduled
surveillance cultures, demonstrated that an-
timicrobial cycling did not influence the emer-
gence of resistance in an ICU adhering to the
principles of antimicrobial de-escalation [128].
Similarly, van Loon et al., who evaluated the
impact of antibiotic cycling using rectal and res-
piratory surveillance cultures and DNA finger-
printing [129], found that overall antibiotic use
increased by 24%, with acquisition of resistant
bacteria being highest with levofloxacin and
pipercillin/tazobactam exposure. Although an-
timicrobial heterogeneity or mixing seems to be
a logical policy, simple cycling of antibiotics
combined with prolonged treatment seems only
to promote further antibiotic resistance [130].
Antimicrobial decolonization strategies
The prophylactic administration of parenteral
antibiotics reduces the occurrence of nosoco-
mial infections in specific high-risk patient
populations requiring intensive care [131,132].
Similarly, topical antibiotic administration (i.e.,
selective digestive decontamination), with or
without concomitant parenteral antibiotics, is
also effective at reducing nosocomial infections
[133–135]. However, the routine use of selec-
tive digestive decontamination has been asso-
ciated with the emergence of antimicrobial re-
sistance [136,137]. Additionally, the results of
recent negative trials for VAP prevention em-
ploying iseganan and chlorhexidine, an antimi-
crobial peptide and antiseptic, respectively, to
decontaminate the oropharynx in mechanically
ventilated patients sheds doubt on the overall
TWENTY-FIFTH ANNUAL ALTEMEIER LECTURE 93
utility of this practice [138,139]. According to
these studies, antimicrobial and non-antimi-
crobial agents should be considered for oral de-
contamination only in appropriate high-risk
ICU patients or to assist in the containment of
outbreaks of infections with multi-drug-resis-
tant bacteria in conjunction with established in-
fection control practices [140].
Shorter courses of antibiotic treatment
Prolonged administration of antibiotics to
ICU patients is an important risk factor for the
emergence of colonization and infection with
antibiotic-resistant bacteria [33,37,130]. There-
fore, recent attempts have been made to reduce
the duration of antibiotic treatment for specific
bacterial infections. Several clinical trials have
found that seven or eight days of antibiotic
treatment is acceptable for most non-bac-
teremic patients with VAP [36,41,106]. Simi-
larly, shorter courses of antibiotic treatment
have been successful in patients at low risk for
VAP [106,118,119], with pyelonephritis [141],
and with community-acquired pneumonia
[142]. In general, the shorter-course regimens
have been associated with significantly lower
risks of emergence of antimicrobial resistance
than the more traditional durations of 14 to 21
days. In the future, more specific markers 
for the presence of bacterial infection (e.g.,
sTREM1) may allow shorter courses of empiric
antibiotic administration in patients without
identified bacterial infection [143,144]. Several
recently published guidelines for the antibiotic
management of nosocomial pneumonia and
severe sepsis recommend the discontinuation
of empiric antibiotic therapy after 48–72 h if
cultures are negative or the signs of infection
have resolved [52,145].
Optimizing pharmacokinetic/pharmocodynamic
(PK/PD) principles
Sublethal antibiotic concentrations can pro-
mote the emergence of resistant pathogens. Op-
timization of antibiotic regimens on the basis
of pharmacokinetic and pharmacodynamic
(PK/PD) principles thus could play a role in
the reduction of antibiotic resistance. The time
the serum drug concentration remains above
the minimum inhibitory concentration (MIC) of
the antibiotic (T  MIC) enhances bacterial
eradication by beta-lactams, carbapenems,
monobactams, glycopeptides, and oxazolidi-
nones. Frequent dosing, prolonged infusion
times, or continuous infusions can increase the
T  MIC and improve clinical and microbio-
logical cure rates [146–150]. In order to maxi-
mize the bactericidal effects of aminoglyco-
sides, clinicians must optimize the maximum
drug concentration (Cmax):MIC ratio. A Cmax:
MIC ratio of 10:1 using once-daily aminogly-
coside dosing (5–7 mg/kg) has prevented 
the emergence of resistant organisms, improved
the clinical response to treatment, and avoided
toxicity [151–153]. The 24-hour area under the
antibiotic concentration curve:MIC ratio (AUIC)
is correlated with fluoroquinolone efficacy and
prevention of resistance development. An
AUIC value 100 has been associated with a
significant reduction in the risk of resistance de-
velopment during therapy [154–155].
CONCLUSION
The ICU should be considered a laboratory
for the conduct of important outcomes research.
Because of the importance of antimicrobial re-
sistance as a determinant of outcome for criti-
cally ill patients, this is a logical location for the
investigation of this important clinical problem.
Although a lack of federal funding and re-
sources may stand in the way of such research,
its importance requires a dedicated group of in-
vestigators willing to devote time and career de-
velopment to this area. Therefore, long-term ef-
forts are required to identify and develop new
and dependable sources of funding to enhance
this scientific agenda, as well as other impor-
tant areas of ICU outcomes research.
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